ARS Pharma enters long-term supply agreement for neffy glass microvials through 2035

ARS Pharmaceuticals, Inc.

Upfront payment of €3 million to Nuova Ompi for glass microvial supply.
Supplier must establish manufacturing force and capabilities to meet obligations.
Annual minimum purchase quantities and capped annual price adjustments specified.
Supply agreement expires December 31, 2035; termination for breach or reasonable business reasons.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.